Abbott Targets Kremers Over Niaspan Clone

Law360, New York (June 4, 2012, 4:30 PM EDT) -- Abbott Laboratories on Friday continued its crusade to protect its cholesterol drug Niaspan by filing a lawsuit against Kremers Urban Pharmaceuticals Inc., accusing the company of infringing Abbott's patents through its efforts to market a generic version of the drug.

The drugmaker's Delaware federal court lawsuit alleges that Kremers is infringing a pair of patents utilized in Abbott's Niaspan product, and that the generics maker should be stopped before it can bring its copycat drug to market.

“If Kremers’s infringement of the [patents] is not enjoined,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.